Lobe Sciences Ltd (TSE:LOBE) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lobe Sciences Ltd. has successfully issued over 69 million common shares to acquire Altemia®, securing exclusive rights to utilize Altemia’s patented product formulations. As a result of the share issuance, Clearway Global, LLC now owns approximately 42% of Lobe Sciences and has become a deemed insider, also providing consulting services to the company. Lobe Sciences continues its commitment to developing innovative medicines for rare diseases and is involved in research with non-hallucinogenic psilocin-based compounds.
For further insights into TSE:LOBE stock, check out TipRanks’ Stock Analysis page.